An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038)

Merck Sharp & Dohme LLC100 enrolled

Overview

The purpose of this study is to determine the effect of an approved medication for adults for an investigational use in pediatric patients 3 months to 17 years for the treatment of complicated intra-abdominal infections or acute pelvic infections.

The duration of treatment is 18 months.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Infections Pelvic Infections

Interventions

MK0826, ertapenem sodiumDRUG

Comparator: Ticarcillin/ClavulanateDRUG

Eligibility

Sex: ALLMin age: 3 MonthsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients aged 3 months to 17 years with intra-abdominal infection or acute pelvic infection Exclusion Criteria: * Immune problems * Kidney problems

Outcomes

Primary Outcomes

Efficacy response at post treatment follow up assessment. Clinical and/or laboratory drug-related SAEs during study drug therapy plus 14 days post therapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.